Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Routine MRI Screening Versus Symptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative and HER2+ Metastatic Breast Cancer (MBC): a Single-centre Randomized Pilot Study

NCT03881605 is registered in ClinicalTrials.gov with Sunnybrook Health Sciences Centre as lead sponsor.

NCT NCT03881605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03881605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Routine MRI Screening Versus Symptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative and HER2+ Metastatic Breast Cancer (MBC): a Single-centre Randomized Pilot Study
Lead sponsor
Sunnybrook Health Sciences Centre
Phase
Not applicable
Overall status
Active, not recruiting
Start date
November 8, 2018
Completion date
December 31, 2025
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, breast neoplasm, her2-positive breast cancer, triple negative breast cancer